Insilico Medicine � PHD1/2 Inhibitor (IBD treatment)

This drug is a small molecule inhibitor of PHD1/2, enzymes that are involved in the degradation of HIFα, a protective regulator in IBD. By inhibiting PHD1/2, the drug aims to reduce HIFα degradation, leading to increased levels of HIF and promotion of barrier-protective gene expression, thus potentially aiding in epithelial barrier healing and decreasing proinflammatory cytokine expression.